AmitGPandyaMD

Dermatology • Mountain View, CA

Professor, Dermatology, University of Texas Southwestern Medical Center, Southwestern Medical School

Join to view full profile

Dr. Pandya is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pandya's full profile

Already have an account?

Office
701 E El Camino Real
Mountain View, CA 94040
Phone+1 650-934-7676

Fax+1 408-735-7297

Education & Training

University of Texas Southwestern Medical CenterResidency, Dermatology, 1988 - 1991
Texas Health Resources (Dallas)Residency, Internal Medicine, 1985 - 1988
University of Texas Southwestern Medical SchoolClass of 1985

Certifications & Licensure

CA State Medical License 2019 - 2025
TX State Medical License 1986 - 2023
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Super Doctor SuperDoctors.com
Fellow (FAAD) American Academy of Dermatology
Join now to see all

Clinical Trials

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris Start of enrollment: 1996 Nov 01
Terminated
Phase 2
Use of KC706 for the Treatment of Pemphigus Vulgaris Start of enrollment: 2007 Nov 01
Completed
Phase 2
Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis Start of enrollment: 2010 Dec 01
Terminated
Not Applicable

Publications & Presentations

PubMed

Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study.
Yuji Yamaguchi, Elena Peeva, Roni Adiri, Pranab Ghosh, Lynne Napatalung
Journal of the American Academy of Dermatology. 2024-12-19
1 citations
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years.
John E Harris, Amit G Pandya, Mark Lebwohl, Iltefat H Hamzavi, Pearl Grimes
Skin Health and Disease. 2024-12-01
1 citations
Effective and durable repigmentation for stable vitiligo: A randomized within-subject controlled trial assessing treatment with autologous skin cell suspension transpl...
Iltefat H Hamzavi, Anand K Ganesan, Bassel H Mahmoud, Eduardo Weiss, Ammar M Ahmed
Journal of the American Academy of Dermatology. 2024-12-01

Journal Articles

International Initiative for Outcomes (INFO) for Vitiligo: Workshops with Vitiligo Patients on Repigmentation
A Pandya, J E Harris, N Elbuluk, The British Journal of Dermatology

Lectures

Skin of Color
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/1/2019
Closing the Gender Gap in Academic Dermatology and Dermatology Leadership: Problems and Solutions
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019

Press Mentions

SPF Is Only the Start When Recommending SunscreensJune 2nd, 2023
Incyte Announces Positive 52-Week Results from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with VitiligoOctober 12th, 2019
Why Aren't There More Black Dermatologists?August 15th, 2019
Join now to see all

Professional Memberships

American Academy of Dermatology - AAD
Fellow

External Links

Amit Pandyahttp://utsouthwestern